ABUS Earnings Preview: Options Price a ±10.3% Move

· The NYC Memo · ABUS reports 2026-11-12

Arbutus Biopharma Corporation reports November 12, 2026. The November 20, 2026 straddle implies ±10.31% against a 2.53% average reaction, with dealers long gamma and max pain at $4.

Live updates

Nov 12 — Ahead of November 12, 2026 earnings, ABUS rose to $3.88 as the implied move compressed from ±11.78% to ±10.31%, implying that the options market is anticipating a narrower post-earnings price swing despite implied volatility climbing to 122.2%.

Nov 11 — Ahead of ABUS earnings on November 12, 2026, the options implied move expanded from ±2.69% to ±11.78% as spot climbed from $3.72 to $3.82, implying expectations for wider share price fluctuations around the release.

Nov 10 — Ahead of November 12, 2026 earnings, ABUS rose from $3.66 to $3.72 as at-the-money implied volatility climbed from 104.5% to 113.1%, implying an expected move of 2.69%.

Arbutus Biopharma Corporation reports on November 12, 2026, with spot at $3.88, down -5.6% over the past month and -28.8% from the prior high. The November 20, 2026 expiry $0.40 straddle implies a 10.31% move and an implied range of $3.48 to $4.28, with atm iv at 122.2%. This pricing outstrips the average realised reaction of 2.53% across 7 prints counted, where shares finished higher 3 times and lower 3 times.

Open interest shows a put call oi of 0.06 and max pain at $4. The dealer lean is long gamma. This positioning means desks must buy dips and sell rips, cushioning volatility and anchoring the tape into the print.

What the market will be watching

The desk focuses on clinical progress and intellectual property developments for Arbutus Biopharma. Options traders will watch updates on the chronic hepatitis B pipeline alongside ongoing lipid nanoparticle patent litigation. Operational spending remains critical, with investors evaluating clinical research costs against the existing financial runway. Management commentary on partner milestones and licensing receipts will indicate the underlying revenue trajectory. Forward guidance covering full-year expenditures and clinical readout timelines will drive volatility. The market needs evidence of pipeline advancement and legal clarity to sustain positive sentiment.

What the options market is pricing

MeasureLevel
PrintNovember 12, 2026
Expiry usedNovember 20, 2026 (8 days out)
Spot$3.88
ATM straddle$0.40
Implied move±10.31% ($3.48 to $4.28)
ATM implied vol122.2%
Put/call open interest0.06
Max pain$4
Net dealer gamma+$0.01mn per 1% move, LONG GAMMA
Heaviest call strike above spot$5 (1,143 contracts)
Heaviest put strike below spot$3.5 (60 contracts)

Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress ABUS between catalysts. That damping disappears the moment the number crosses the tape.

How the stock has reacted before

ReportNext-day move
Q2 2026, Aug 12-1.71%
Q1 2026, May 13+0.00%
Q4 2025, Mar 23+4.25%
Q3 2025, Nov 13-5.79%
Q2 2025, Aug 6+1.76%
Q4 2024, Mar 27-2.39%
Q4 2024, Jan 13+1.82%

Across the last 7 prints the average absolute reaction is 2.53%, with 3 higher and 3 lower. The best was +4.25% and the worst -5.79%. Options are asking ±10.31%, which is 7.78 points richer than the realised average, the premium seller's case.

Where the stock is trading

MeasureLevel
Spot$3.88
52-week range$3.50 to $5.45
Position in that range19%
From the 52-week high-28.8%
From the 52-week low+10.9%
Past week-4.4%
Past month-5.6%
Past three months-15.3%
50-day average$4.50
200-day average$4.48

How the options market is pricing it

The November 20, 2026 straddle marks $3.48 to $4.28 as the range the options market is paying for into the print, with ATM implied vol at 122% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically ABUS has moved 2.53% on earnings against the ±10.31% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.

Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for ABUS before the print.

Data as of November 12, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.

Related: ABUS options memo

More earnings previews